Download presentation
Presentation is loading. Please wait.
1
The Drug Development Process
From Discovery to Market This workforce solution was funded by a grant awarded under the President’s Community-Based Job Training Grants as implemented by the U.S. Department of Labor’s Employment and Training Administration. The solution was created by the grantee and does not necessarily reflect the official position of the U.S. Department of Labor. The Department of Labor makes no guarantees, warranties, or assurances of any kind, express or implied, with respect to such information, including any information on linked sites and including, but not limited to, accuracy of the information or its completeness, timeliness, usefulness, adequacy, continued availability, or ownership. This solution is copyrighted by the institution that created it. Internal use by an organization and/or personal use by an individual for non-commercial purposes is permissible. All other uses require the prior authorization of the copyright owner.
2
The Drug Development Process
From the time a compound is discovered to the time it hits the market, the entire process takes approximately 15 years.
3
The Drug Development Process
30 70 10,000 100 250 20 Periapproval Phase III Phase II Research Discovery Development Phase I Phase IV Preclinical IND Filed Phase IIIb NDA Approved Time to Market 15 Years Life of Drug Patent 20 years The Discovery phase occurs at a pharmaceutical company or university. 10,000 compounds are researched. Of the 10,000 compounds, 250 will make it to the Development phase. The first part of the Development phase, is Preclinical testing. In the preclinical phase, animal studies are conducted. New compounds cannot be tested in humans until certain studies are conducted in animals to demonstrate safe dose levels. When the studies are completed, the pharmaceutical company will file an “IND,” Investigational New Drug exemption application, with the FDA. When the IND is approved, the compound can be tested in humans. The Phase I, II, and III trials are human trials. After specific studies are completed, the pharmaceutical company will file an “NDA,” New Drug Application, with the FDA. If an NDA is approved, the pharmaceutical company will begin market research to prepare for commercialization of the drug.
4
Objectives of Drug Discovery
Will the drug fulfill an unmet medical need? Does the drug work? Does the drug fit the company portfolio? Does the drug have obvious undesirable properties? Can the drug be formulated easily? Can it be economically manufactured?
5
Sources of a New Drug New Drug Synthetic Novel Chemical Serendipity
Random Screening New Drug Old Drug Found to have a New Use Chemicals Found in Humans (Replacement Therapy) Modification of a Known Drug Natural Chemical Not Found in Humans that has Activity as a Drug
6
Chemistry, Manufacturing, and Controls
Drug Development: CMC Chemistry, Manufacturing, and Controls Drug Substance: New Chemical Entity (NCE), Test Article, Active Pharmaceutical Ingredient (API) Drug Product: Formulated Drug, including container and packaging
7
Drug Development: CMC Chemistry Characterize drug substance
Assay development Impurity profile Formulation development Stability of drug substance and drug product
8
Drug Development: CMC Manufacturing
Method of synthesis (Expression system) Purification Formulation process Packaging and labeling Storage
9
Drug Development: CMC Controls Process control Quality control
Quality assurance
10
Drug Development: CMC Complete physical and chemical characterization
Well-defined, controlled manufacturing process Compliance with cGMPs (current Good Manufacturing Practices)
11
Drug Development How long does it take for a drug to go from discovery to market? What is CMC? Name two objectives of drug discovery.
12
Drug Development: Preclinical
Periapproval Phase III Phase II Research Discovery Development Phase I Phase IV Preclinical IND Filed Phase IIIb NDA Approved Laboratory and animal testing - Toxicology and pharmacokinetics 1 - 3 years - Studies with various species and durations 250 compounds
13
Drug Development: Preclinical
International Conference on Harmonization (ICH) Guidelines Joint approval between Europe, Japan, and USA Requirements: safety pharmacology genetic toxicology animal toxicology exposure assessment (i.e., ADME)
14
Drug Development: Preclinical
Safety Pharmacology In vitro and in vivo studies conducted to determine whether this compound has any effects on: Brain – central nervous system Lungs – respiratory system Heart – cardiovascular system
15
Drug Development: Preclinical
Genetic Toxicology In vitro and in vivo studies conducted to determine whether this compound has the potential to induce mutations and chromosomal damage bacterial mutation cytogenetics mammalian gene mutation
16
Drug Development: Preclinical
Animal Toxicity Studies Single- and multiple-dose toxicity studies Developmental and reproductive toxicology (DART) Carcinogenicity Special toxicity studies/evaluations Immunotoxicity Immunogenicity Photosensitization
17
Drug Development: Preclinical
Acute Toxicology Studies Animals given a single dose by the intended route of exposure and monitored for 14 days Clinical signs Information on overdose effects Minimum and median lethal dose Repeat-Dose Toxicity Studies Study cumulative effects Extensive clinical evaluation of test animals physical, neurologic, and ophthalmic exams ECG evaluation Clinical and anatomic pathology analyses
18
Drug Development: Preclinical
Goals of Acute and Repeat-Dose Toxicity Studies Target organ toxicity Dose response Biomarkers Safety Requirements for Phases I and II EU and I to III Japan and USA
19
Drug Development: Preclinical
Developmental and Reproductive Toxicology (DART) Effects on male and female fertility Teratogenic potential (embryo-fetal toxicity) Effect on peri- and post-natal development of offspring, including maternal development Supports inclusion of women in clinical trials
20
Drug Development: Preclinical
Carcinogenicity Studies Test the potential to produce tumors in animals Lifetime exposure in rats and mice (2 years) Large doses (MTD) are generally used Effects may be due to exaggerated pharmacodynamics Not always needed in advance of safety and efficacy trials
21
Drug Development: Preclinical
Exposure Assessment A few different terms: toxicokinetics, pharmacokinetics, ADME, bioanalytical These all describe the science of determining the levels of the drug that were absorbed into the blood stream or tissues and how long it stayed in the system. Key to determining dose levels and frequency the drug can be taken (e.g., two times/day, once/week, every 4 hours, etc.)
22
Drug Development: Preclinical
Definition “ADME” Absorption – does the compound get into the body? Distribution – where does it go? Metabolism – what happens to it when in the body? Excretion – how does it get out?
23
Filing an IND Information filed with regulatory agency providing the results from the preclinical phase testing Chemistry, manufacturing, and control information Pharmacology and toxicology information Clinical information/ proposed clinical studies to be conducted Purpose Required prior to conducting clinical studies in humans Demonstrates the drug is safe enough to administer to humans Represents the initiation of the first phase of clinical development i.e., Phase I or First in Human (FIH) studies Duration and Success Rates 30 days for regulatory agency to review 88% are approved
24
Drug Development What organ systems do safety pharmacology studies test? What are DART studies? What are carcinogenicity studies? What does “ADME” stand for? If your IND is approved, what happens next?
25
Drug Development: Clinical
Periapproval Phase III Phase II Research Discovery Development Phase I Phase IV Preclinical IND Filed Phase IIIb NDA Approved Is it safe? Determine dosage levels healthy volunteers Up to 12 months 100 compounds
26
Drug Development: Clinical
Initial introduction of drug in humans – Phase I 20-80 volunteers May be patients for life-threatening indications Single rising dose monitor clinical signs, laboratory tests, and PK escalate based on previous dose Multiple rising dose trial duration usually < 2 weeks 70% move to Phase IIa
27
Drug Development: Clinical
Periapproval Phase III Phase II Research Discovery Development Phase I Phase IV Preclinical IND Filed Phase IIIb NDA Approved Is it safe and does it work? Refine dosage levels patients Up to 2 years 70 compounds
28
Drug Development: Clinical
Proof of Concept (POC) Initial evaluation of safety and efficacy of drug in patients patients Dose range based on results of Phase I studies Usually done in successive steps i.e., Phase IIa and Phase IIb May be done at multiple sites to enhance recruiting 48% move to Phase III
29
Drug Development: Clinical
Periapproval Phase III Phase II Research Discovery Development Phase I Phase IV Preclinical IND Filed Phase IIIb NDA Approved Is it safe? Does it work? Any side effects? 1, ,000 patients Up to 4 years 30 compounds
30
Drug Development: Clinical
Pivotal Studies Statistical efficacy – 100s to 1,000s of patients Reproducible - two studies Multiple centers Placebo or other controls Unbiased - blinded, randomized Objectives of Phase III Confirms therapeutic efficacy Determines product labeling Definitive efficacy in target population Characterize safety Patient variations (genetics, life style) Extent of adverse effects Concomitant therapies Concomitant conditions (liver impairment, pregnancy, etc.)
31
Drug Development What key question should Phase I trials answer?
How many patients might be involved on a Phase II trial? Name two objectives of Phase III.
32
Drug Development: Clinical
Periapproval Phase III Phase II Research Discovery Development Phase I Phase IV Preclinical IND Filed Phase IIIb NDA Approved New Drug Application (NDA) is prepared and submitted to regulatory authorities 2 months - 7 years Phase IIIb studies sometimes conducted
33
Drug Development: Market
After NDA approval is obtained, the pharmaceutical company will market the drug. There are regulations for product labeling, naming, and marketing (TV and radio commercials and print ads).
34
Drug Development: Market
Periapproval Phase III Phase II Research Discovery Development Phase I Phase IV Preclinical IND Filed Phase IIIb NDA Approved "Real World" studies Validate clinical work and/or safety hypothesis Usually require large numbers of patients Up to years
35
Drug Development: Market
Objectives of Phase IV - Postmarketing Studies Continue collecting safety/efficacy data after early market approval Collect cost-effectiveness data Collect data for switch from prescription to over-the-counter Objectives of Phase IV - Line Extensions New clinical indications New dosage forms and formulation development Extend label (market support)
36
Drug Development: Market
30 70 10,000 100 250 20 Periapproval Phase III Phase II Research Discovery Development Phase I Phase IV Preclinical Phase IIIb IND Filed NDA Approved The industry spends, on average, approximately $500 to $800 million to bring a new medical therapy to market
37
Drug Development Activity
Let’s review a product label.
Similar presentations
